MolDX: Blood Product Molecular Antigen Typing

Molecular blood product antigen typing is covered for patients expected to need long-term frequent transfusions, when serologic testing is confounded by autoantibodies or other reactivity, when typing reagents are unavailable, or when serologic discrepancies exist (e.g., rare Rh variants). Laboratory-developed tests may be covered if validated by a technical assessment; single-gene tests are generally not reasonable and require strong documentation. Testing is generally not expected for routine perioperative transfusion management (cardiac, hip, knee procedures) or for patients with serologically identifiable alloantibodies who do not require frequent long-term transfusions, and all testing must meet germline-testing policy requirements with medical necessity documented in the record.

"Molecular phenotyping is covered for patients anticipated to require long-term, frequent transfusions to prevent alloantibody development (e."